Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Lymphoma during Pregnancy: A Multicentre Study By the Australasian Lymphoma Alliance

Pietro R Di Ciaccio, Belinda Campbell, Kylie D Mason, Mohamed Shanavas, Matthew Greenwood, Gareth P Gregory, Renee Eslick, Giselle Kidson-Gerber, Catherine Tang, Kirk L Morris, Portia Smallbone, Xavier Badoux, Michael J Shipton, Sean J McKeague, Jenna Langfield, Kathryn Goss, Nada Hamad

Blood (2021) 138 (Supplement 1): 882.

https://doi.org/10.1182/blood-2021-150538

Published: 2021

Journal Articles

Capturing the Lived Experiences of Women with Lymphoma in Pregnancy: An Australasian Lymphoma Alliance Study

Georgia Mills, Pietro R Di Ciaccio, Catherine Tang, Verity L Chadwick, Kylie D Mason, Belinda Campbell, Mohamed Shanavas, Kirk L Morris, Matthew Greenwood, Giselle Kidson-Gerber, Renee Eslick, Xavier Badoux, Costas K. Yannakou, Shane A Gangatharan, Nada Hamad

Blood (2021) 138 (Supplement 1): 4099.

https://doi.org/10.1182/blood-2021-152065

Published: 2021

Journal Articles

Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study

Judith Trotman, Peter Presgrave, Duncan P. Carradice, Douglas Stuart Lenton, Maher Gandhi, Tara Cochrane, Xavier Badoux, Gloria Nkhoma, Belinda Butcher, Michael Fulham, Anna Johnston

Blood (2021) 138 (Supplement 1): 2428.

https://doi.org/10.1182/blood-2021-146343

Published: 2021

Journal Articles

Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status

Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Devinder Gill, MD MRCP, FRCPath, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Leanne Berkahn, MD, David Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Rosemary Anne Harrup, MD, Naomi J. Mackinlay, MB BS, FRACP, FRCPA, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Xavier Badoux, MBBS, AB, FRACP, FRCPA, Oliver Giles Best, PhD BSc, Bryone Jean Kuss, PhD BMBS, FRCPA, FRACP

Blood (2018) 132 (Supplement 1): 4432.

https://doi.org/10.1182/blood-2018-99-114064

Published: 2018

Journal Articles

Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC+G) Versus Chlorambucil Plus Obinutuzumab (Cbl+G) As Front-Line Therapy

Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Jane A. Freeman, BA, FRACP, FRCPA, MBBS, MPhil, MSc, Xavier Badoux, MBBS, AB, FRACP, FRCPA, Richard Eek, MBCHB, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Naomi J. Mackinlay, MB BS, FRACP, FRCPA, Nicholas E. Murphy, FRCPA, MBBS, FRACP, Duncan P. Carradice, MBBS, FRCPA, FRACP, Ann C. Solterbeck, BSc(hons) MSc PhDAStat, Oliver Giles Best, PhD BSc, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Bryone J. Kuss, PhD BMBS, FRCPA, FRACP

Blood (2018) 132 (Supplement 1): 3144.

https://doi.org/10.1182/blood-2018-99-116287

Published: 2018

Journal Articles

BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma

Constantine S. Tam, MD, Hang Quach, MBBS, MD, Andrew Nicol, Xavier Badoux, Hannah Rose, H. Miles Prince, MD FRACP, FRCPA, Michael F. Leahy, FRACP,FRCPath,FRCP, Richard Eek, MBCHB, Nicholas Wickham, FRCPA,FRACP,FRCPath, Sushrut S. Patil, FRACP, FRCPA, Jane Huang, MD, Xiaoping Zhang, MD PhD, Lai Wang, PhD, Eric Hedrick, MD, William Novotny, Ian W. Flinn, MD PhD

Blood (2017) 130 (Supplement 1): 1745.

https://doi.org/10.1182/blood.V130.Suppl_1.1745.1745

Published: 2017

Journal Articles

A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4)

Philip Young-Ill Choi, Fernando Roncolato, Xavier Badoux, Sundra Ramanathan, Shir-Jing Ho, Beng H. Chong

Blood (2015) 126 (4): 500–503.

https://doi.org/10.1182/blood-2015-03-631937

Published: 2015

Includes: Supplemental data

Journal Articles

Genomic Profiling In Fit, Elderly Patients Receiving Oral Fludarabine, Oral Cyclophosphamide and Intravenous Rituximab (ALLG CLL5 OFOCIR trial) As Initial Treatment Of Chronic Lymphocytic Leukemia (CLL)

XAVIER BADOUX, MBBS FRACP FRCPA, Giles Best, BSc (Hons) Ph.D., Sara Gabrielli, Miss, Ying Zhu, PhD, Melanie Hayes, PhD, Bryone J Kuss, MBBS, PhD, FRCPA, William Stevenson, MBBS, PhD, Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA

Blood (2013) 122 (21): 1624.

https://doi.org/10.1182/blood.V122.21.1624.1624

Published: 2013

Journal Articles

Triple Therapy For Immune Thrombocytopenia: A Novel Combination Of Conventional Strategies To Safely Sustain Platelet Counts In ITP

Philip Young-Ill Choi, BA BSc(Med) MBBS FRACP FRCPA, Soo-Chin Ng, FRCP, FRCPA, Christine Lee, MD, Fernando Roncolato, MBBS FRCPA FRACP, Xavier Badoux, MBBS FRACP FRCPA, Amanda J. Hugman, MBBS FRCPA FRACP, Sundra Ramanathan, MBBS (Hons) FRACP FRCPA, Shir-Jing Ho, MBBS, FRACP, FRCPA, Szu-Hee Lee, MBBChir, PhD, FRCPA, FRACP, Beng Chong, MBBS FRCPA FRACP PhD

Blood (2013) 122 (21): 1084.

https://doi.org/10.1182/blood.V122.21.1084.1084

Published: 2013

Journal Articles

Clintrial Refer- a Mobile App To Connect Patients With Local Clinical Trials

Blood (2013) 122 (21): 5600.

https://doi.org/10.1182/blood.V122.21.5600.5600

Published: 2013

Journal Articles

Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab

Sarit Assouline, Valeria Buccheri, MD; PhD., Alain Delmer, MD, Gottfried Doelken, MD, Gianluca Gaidano, MD, PhD, Christine McIntyre, Mike Brewster, Florence Hourcade-Potelleret, PhD, Pakeeza Sayyed, Xavier Badoux, MB BS FRACP FRCPA

Blood (2012) 120 (21): 1637.

https://doi.org/10.1182/blood.V120.21.1637.1637

Published: 2012

Journal Articles

Combination Therapy with Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial

Alessandra Ferrajoli, MD, Susan O'Brien, MD, William G. Wierda, MD, PhD, Stefan Faderl, MD, Xavier Badoux, MD, Zeev Estrov, Ellen Schlette, MD, Susan C. Smith, BS, Ana B. Ayala, ADN, Lorenzo Falchi, MD, Steliana Calin, MD, Hagop M. Kantarjian, MD, Michael J Keating, MD

Blood (2011) 118 (21): 1788.

https://doi.org/10.1182/blood.V118.21.1788.1788

Published: 2011

Journal Articles

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia

Sameer A. Parikh, Michael J. Keating, Susan O'Brien, Xuemei Wang, Alessandra Ferrajoli, Stefan Faderl, Jan Burger, Charles Koller, Zeev Estrov, Xavier Badoux, Susan Lerner, William G. Wierda

Blood (2011) 118 (8): 2062–2068.

https://doi.org/10.1182/blood-2011-01-329177

Published: 2011

Journal Articles

Combination of Ofatumumab and Lenalidomide In Patients with Relapsed Chronic Lymphocytic Leukemia: Initial Results of a Phase II Trial

Xavier Badoux, MD, Susan O'Brien, MD, William G. Wierda, MD, PhD, Stefan Faderl, MD, Zeev Estrov, MD, Kimberly Yerrow, BSN, Hagop M. Kantarjian, MD, Michael J Keating, MD, Alessandra Ferrajoli, MD

Blood (2010) 116 (21): 2464.

https://doi.org/10.1182/blood.V116.21.2464.2464

Published: 2010

Journal Articles

Decitabine and Gemtuzumab Ozogamicin In Patients with Advanced Myelofibrosis

Ali Al-Ameri Al-Ameri, MD, Hagop Kantarjian, MD, Asifa Malik, MD, Xavier Badoux, MD, Michael Andreeff, MD, PhD, Alfonso Quintas-Cardama, MD, Gautam Borthakur, MD

Blood (2010) 116 (21): 5061.

https://doi.org/10.1182/blood.V116.21.5061.5061

Published: 2010

Journal Articles

Phase II Study of Dasatinib In Patients with Relapsed Chronic Lymphocytic Leukemia.

Ali M Al-Ameri, MD, Xavier Badoux, MD, Alessandra Ferrajoli, MD, William G. Wierda, MD, PhD, Luis Fayad, MD, Zeev Estrov, MD, Susan Bickel, RN, Michael J Keating, MD, Susan O'Brien

Blood (2010) 116 (21): 4488.

https://doi.org/10.1182/blood.V116.21.4488.4488

Published: 2010

Journal Articles

The Combination of Lenalidomide and Rituximab Induces Complete and Partial Responses In Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.

Alessandra Ferrajoli, MD, Xavier Badoux, MD, Susan O'Brien, William G. Wierda, MD, PhD, Stefan Faderl, MD, Zeev Estrov, MD, Manolo Pasia, BSN, Susan Lerner, MS, BA, Hagop Kantarjian, MD, Michael J Keating, MD

Blood (2010) 116 (21): 1395.

https://doi.org/10.1182/blood.V116.21.1395.1395

Published: 2010

Journal Articles

Infectious Events In Patients with Chronic Myeloid Leukemia Treated with Nilotinib as a Front Line Therapy and After Imatinib Failure

Ali M Al-Ameri, MD, Jorge E. Cortes, MD, Hagop Kantarjian, MD, Elizabeth Burton, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Xavier Badoux, MD, Susan O'Brien, Gloria Mattiuzzi, MD

Blood (2010) 116 (21): 1233.

https://doi.org/10.1182/blood.V116.21.1233.1233

Published: 2010

Journal Articles

Retrospective Analysis of the Experience with Rituximab and Methylprednisone In Elderly Patients with CLL

Xavier Badoux, MD, Ali M Al-Ameri, Susan O'Brien, MD, William G. Wierda, MD, PhD, Jan A. Burger, MD, PhD, Stefan Faderl, MD, Zeev Estrov, MD, Susan Lerner, MS, BA, Michael J Keating, MD, Alessandra Ferrajoli, MD

Blood (2010) 116 (21): 4636.

https://doi.org/10.1182/blood.V116.21.4636.4636

Published: 2010

NARROW

Lymphoma during Pregnancy: A Multicentre Study By the Australasian Lymphoma Alliance

Capturing the Lived Experiences of Women with Lymphoma in Pregnancy: An Australasian Lymphoma Alliance Study

Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study

Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status

Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC+G) Versus Chlorambucil Plus Obinutuzumab (Cbl+G) As Front-Line Therapy

BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma

A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4)

Genomic Profiling In Fit, Elderly Patients Receiving Oral Fludarabine, Oral Cyclophosphamide and Intravenous Rituximab (ALLG CLL5 OFOCIR trial) As Initial Treatment Of Chronic Lymphocytic Leukemia (CLL)

Triple Therapy For Immune Thrombocytopenia: A Novel Combination Of Conventional Strategies To Safely Sustain Platelet Counts In ITP

Clintrial Refer- a Mobile App To Connect Patients With Local Clinical Trials

Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab

Combination Therapy with Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia

Combination of Ofatumumab and Lenalidomide In Patients with Relapsed Chronic Lymphocytic Leukemia: Initial Results of a Phase II Trial

Decitabine and Gemtuzumab Ozogamicin In Patients with Advanced Myelofibrosis

Phase II Study of Dasatinib In Patients with Relapsed Chronic Lymphocytic Leukemia.

The Combination of Lenalidomide and Rituximab Induces Complete and Partial Responses In Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.

Infectious Events In Patients with Chronic Myeloid Leukemia Treated with Nilotinib as a Front Line Therapy and After Imatinib Failure

Retrospective Analysis of the Experience with Rituximab and Methylprednisone In Elderly Patients with CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only